Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- ULCER SIZE CHANGE
研究概览
简要总结
INTRODUCTION: Vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of human and material resources.The cure with autologous platelet rich plasma (autologous PRP) has demonstrated in different studies a decrease in the cicatrization time comparing to conventional methods in hospital levels, which becomes interesting contrasting its efficacy in primary care.
AIM:Evaluate the efficacy of the autologous PRP in the treatment of vascular ulcers, comparing to the conventional treatment ( cure with humid environment), in primary care patients with chronic venous insufficiency in C-6 degree (CEAP classification).
DESIGN: A study will be executed, which will consist in a randomized clinical test, multicentered, in parallel groups and opened. 150 patients suffering of venous vascular ulcers will be studied, who will be between the age of 40-100 years old, and who will be attached to 10 health centers. Variables for the identification, following, result and patient profile have been defined. Emphasize the variables of "ulcer area decreasing", "CIVIQ index", "% one cure per week".
详细描述
Vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of human and material resources.The cure with autologous platelet rich plasma (autologous PRP) has demonstrated in different studies a decrease in the cicatrization time comparing to conventional methods in hospital levels, which becomes interesting contrasting its efficacy in primary care.The aim of this study is to evaluate the efficacy of the autologous PRP in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous insufficiency in C-6 degree (CEAP classification). It is a study which will consist in a randomized clinical test, multicentered, in parallel groups and opened 150 patients suffering of venous vascular ulcers will be studied. Variables for the identification, following, result and patient profile have been defined. Emphasize the variables of "ulcer area change", "CIVIQ index", "% one cure per week".
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients from Barakaldo and Bilbao, who come to the treatment room at health centers in these towns belong to the OSI Ezkerraldea-Enkarterri-Cruces of Osakidetza-Basque Health Service.
- •Men or women older than 18 years old.
- •Patients with chronic venous insufficiency stage C-6 of the CEAP classification.
- •Patients with vascular ulcers unresponsive to conventional treatment over a 2 months period or recurrence of previous venous ulcers.
- •Patients who present an analytical before entering the studio, platelets and red blood cell count and hematocrit in normal range
- •Ulcers whose diameter size is 30cm² or less.
- •Greater Ankle Arm Index 0.8 and less than 1.
- •Patients with recent analytic with number platelet and red blood cell count and hematocrit normal range.
- •Patients with recent analytic negative to: Syphilis serology, Hepatitis B: HBsAg, Hepatitis C: Anti-HCV tests genomic nucleic acid amplification (NAT), HIV I / II: Anti-HIV I / II.
- •Self or family support sufficient to move patients to the health center.
- •Written informed consent of the patient
排除标准
- •Patients on chronic immunosuppressive or retroviral.
- •Coagulopathy
- •Patients with chronic infectious diseases.
- •Patients treated with radiotherapy or chemotherapy, or history of neoplasia.
- •Patients with more than two active ulcers.
- •Pregnant or childbearing potential not want to use contraception.
- •Women breastfeeding.
- •Patients with active infection or febrile syndrome at baseline.
- •People who are taking a drug under clinical investigation or participated in any study under clinical investigation in the previous 30 days.
研究组 & 干预措施
Platelet-Rich Plasma
Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
干预措施: Platelet-Rich Plasma (Drug)
Usual treatment
Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
干预措施: Usual treatment (Other)
结局指标
主要结局
ULCER SIZE CHANGE
时间窗: Change from baseline at 9 weeks
Change from baseline at 9 weeks of the surface area of the ulcer, in cm2, measured using ImageJ software from the weekly the photographs of the wound.
次要结局
- QUALITY OF LIFE (INDEX CIVIQ)(Change from baseline at 9 weeks)
- Change of the percentage OF PATIENTS WITH A ONLY ONE TREATMENT FOR WEEK(Change from baseline at 9 weeks)
研究者
Kepa M. San Sebastián Moreno
Physician
Basque Health Service